MTOR and fleck corneal dystrophy: Considering the pharmacological effect of sirolimus and elevated mTOR function, patients with FCD caused by a pathogenic variant of MTOR or other MTOR‐related genes respond more efficiently to sirolimus than those with condition not related to elevated mTOR function.